The Priority Review

Tag

Lilac Biosciences

1 story

  1. Policy

    Lilac Biosciences names Adriana Coll De Peña, Ph.D., CEO

    Lilac Biosciences Inc. announced that Adriana Coll De Peña, Ph.D., joined the company on September 15, 2026, as chief executive officer. The company said the new CEO will grow the ModQuantTM platform beyond its first RNA modification kit into a broader set of RNA tools for research and therapeutic discovery.